Results 91 to 100 of about 3,407,318 (341)
Anti-platelet agents in pediatric cardiac practice
Annals of Pediatric Cardiology, 2013 Pediatric patients with a variety of congenital and acquired cardiac conditions receive antithrombotic therapy. Many of the indications are empirical, and have either not been proven in controlled studies or are extrapolated from adult studies.
Sweta Mohanty, Balu Vaidyanathan
doaj +1 more source
Mechanism of action of novel NO-releasing furoxan derivatives of aspirin in human platelets [PDF]
, 2006 1 Incorporation of a nitric oxide (NO)-releasing moiety in aspirin can overcome its gastric side effects. 2 We investigated the NO-release patterns and antiplatelet effects of novel furoxan derivatives of aspirin (B8 and B7) in comparison to existing ...
Adriano G Rossi +61 more
core +2 more sources
Korean Journal of Anesthesiology, 2017 Platelets play pivotal roles in hemostasis as well as pathological arterial thrombosis. The combination of aspirin and a P2Y12 inhibitor has become the mainstay therapy in the ageing population with cardiovascular conditions, particularly during and ...
Michael A. Mazzeffi +3 more
semanticscholar +1 more source
ChemistryEurope, EarlyView.Hyperpolarization by parahydrogen‐induced polarization enhances the sensitivity of nuclear magnetic resonance spectroscopy of amino acids, peptides, mini‐proteins, and biopolymers using nonnatural amino acids with unsaturated side chains up to three orders of magnitude.
Gerd Buntkowsky
wiley +1 more source
COPD and cardiovascular disease [PDF]
, 2018 COPD is one of the major public health problems in people aged 40 years or above. It is currently the 4th leading cause of death in the world and projected to be the 3rd leading cause of death by 2020.
André, S +6 more
core +4 more sources
Clinical Pharmacology &Therapeutics, EarlyView.From the nationwide multicenter consortium, 8,163 patients undergoing drug‐eluting stent implantation were classified according to the presence of the CYP2C19 loss‐of‐function (LoF) allele: rapid or normal metabolizers (RMs/NMs) vs. intermediate or poor metabolizers (IMs/PMs), and clinical risk was stratified using the CHADS‐P2A2RC and TRS 2°P scores ...
Hyun Woong Park +22 more
wiley +1 more source
Contemporary NSTEMI management: the role of the hospitalist. [PDF]
, 2019 Non-ST-segment elevation myocardial infarction (NSTEMI) is defined as elevated cardiac biomarkers of necrosis in the absence of persistent ST-segment elevation in the setting of anginal symptoms or other acute event.
Amin, Alpesh +9 more
core +1 more source
Elevated Baseline Serum Fibrinogen: Effect on 2-Year Major Adverse Cardiovascular Events Following Percutaneous Coronary Intervention. [PDF]
, 2017 BackgroundElevated fibrinogen is associated with short-term major adverse cardiovascular events (MACE) after percutaneous coronary intervention, but the relation with late MACE is unknown.Methods and resultsBaseline demographics and 2-year MACE were ...
Ang, Lawrence +7 more
core +1 more source
Safety of Needle Electromyography in Critically Ill Patients [PDF]
, 2020 Introduction: To evaluate the safety of needle electromyography (EMG) in critically ill intensive care unit (ICU) patients who are on anticoagulants and have comorbidities that increase the risk of bleeding and infections.
Bollu, Pradeep +5 more
core +2 more sources
Clinical Pharmacology &Therapeutics, EarlyView.Pregabalin and duloxetine are widely prescribed non‐opioid medications for chronic musculoskeletal pain. Pregabalin may increase the risk of heart failure, and duloxetine increases heart rate and blood pressure; however, little is known about their comparative cardiovascular safety.
Sachalee Campbell +11 more
wiley +1 more source